Investors question Lexington startup’s dry eye treatment

//Investors question Lexington startup’s dry eye treatment

Investors question Lexington startup’s dry eye treatment

Aldeyra Therapeutics CEO Todd Brady called 2019 a "remarkable" year for the company, but investors are questioning the Lexington-based company's lead treatment. Aldeyra (Nasdaq: ALDX) has been hoping to break into the multi-billion-dollar eye treatment market for several years. The 15-year-old company hopes to become a commercial-stage company in the next year or so through its most advanced product candidate: reproxalap, which the company in the last stages of testing as a treatment for dry eye…

Article by [author-name] (c) Health Care News - Health Care News Headlines | Bizjournals.com - Read full story here.

By | 2019-12-03T17:42:49+00:00 December 3rd, 2019|Healthcare|

About the Author: